Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions
LGND Stock Forecast
Ligand Pharmaceuticals stock forecast is as follows: an average price target of $140.50 (represents a 22.56% upside from LGND’s last price of $114.64) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
LGND Price Target
The average price target for Ligand Pharmaceuticals (LGND) is $140.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $157.00 to $130.00. This represents a potential 22.56% upside from LGND's last price of $114.64.
LGND Analyst Ratings
According to 6 Wall Street analysts, Ligand Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LGND stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ligand Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Joseph Pantginis | H.C. Wainwright | $157.00 | $108.31 | 44.95% | 36.95% |
| Oct 02, 2024 | Leland Gershell | Oppenheimer | $135.00 | $99.95 | 35.07% | 17.76% |
| Jul 30, 2024 | Douglas Miehm | RBC Capital | $130.00 | $108.75 | 19.54% | 13.40% |
| Jul 09, 2024 | Matt Hewitt | Craig-Hallum | $140.00 | $86.88 | 61.14% | 22.12% |
| Jun 28, 2024 | Joseph Pantginis | H.C. Wainwright | $144.00 | $82.33 | 74.91% | 25.61% |
| Dec 23, 2022 | Roth Capital | $90.00 | $67.32 | 33.69% | -21.49% |
The latest Ligand Pharmaceuticals stock forecast, released on Oct 21, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $157.00, which represents a 44.95% increase from the stock price at the time of the forecast ($108.31), and a 36.95% increase from LGND last price ($114.64).
Ligand Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $146.00 | $141.20 |
| Last Closing Price | $114.64 | $114.64 | $114.64 |
| Upside/Downside | -100.00% | 27.36% | 23.17% |
In the current month, the average price target of Ligand Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ligand Pharmaceuticals's last price of $114.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 03, 2024 | RBC Capital | Buy | Buy | Hold |
| Oct 03, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Oct 02, 2024 | Oppenheimer | Outperform | Initialise | |
| Aug 12, 2024 | Benchmark | Buy | Buy | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 30, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 30, 2024 | RBC Capital | Outperform | Initialise | |
| Jul 09, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 23, 2022 | Roth Capital | Buy | Buy | Hold |
| Jul 05, 2022 | Barclays | Overweight | Overweight | Hold |
| Feb 22, 2022 | Benchmark | Buy | Buy | Hold |
| Feb 18, 2022 | Barclays | Overweight | Overweight | Hold |
Ligand Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 18, 2024. The company gave LGND a "Buy" rating, the same as its previous rate.
Ligand Pharmaceuticals Financial Forecast
Ligand Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $28.10M | $32.87M | $26.37M | $43.98M | $50.38M | $66.09M | $57.42M | $45.69M | $72.47M | $64.83M | $84.67M | $55.15M | $69.99M | $41.85M | $41.42M | $33.16M | $27.00M | $24.81M | $24.99M | $43.48M | $56.16M | $29.27M |
| Avg Forecast | $52.90M | $46.25M | $43.15M | $36.30M | $39.03M | $40.60M | $33.04M | $27.92M | $25.64M | $27.22M | $24.74M | $33.55M | $44.09M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $46.74M | $32.35M |
| High Forecast | $55.59M | $48.60M | $45.35M | $38.15M | $39.50M | $41.41M | $33.04M | $27.92M | $25.92M | $28.61M | $26.00M | $35.26M | $46.34M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $56.09M | $38.82M |
| Low Forecast | $50.15M | $43.84M | $40.90M | $34.41M | $38.19M | $39.78M | $33.04M | $27.92M | $25.37M | $25.81M | $23.45M | $31.80M | $41.80M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $37.39M | $25.88M |
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 1.21% | 1.07% | 1.31% | 1.14% | 1.72% | 1.52% | 1.34% | 1.11% | 1.10% | 1.19% | 0.88% | 1.23% | 0.93% | 1.38% | 1.25% | 1.08% | 1.11% | 1.19% | 1.14% | 1.20% | 0.90% |
Ligand Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $27.92M, with a low forecast of $27.92M, and a high forecast of $27.92M. LGND's average Quarter revenue forecast represents a -0.63% decrease compared to the company's last Quarter revenue of $28.10M (Dec 23).
Ligand Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $-3.36M | $23.46M | $2.56M | $-16.79M | $-55.81M | $13.38M | $13.26M | $5.21M | $21.17M | $30.37M | $64.38M | $3.44M | $-11.07M | $7.40M | $12.78M | $7.32M | $-12.36M | $-1.61M | $-625.00K | $-795.55M | $41.28M | $13.34M |
| Avg Forecast | $23.48M | $20.52M | $19.15M | $16.11M | $17.32M | $18.02M | $14.66M | $6.03M | $11.38M | $12.08M | $10.98M | $5.48M | $7.03M | $223.10K | $219.68K | $4.33M | $378.92K | $341.95K | $415.70K | $18.57M | $329.95K | $262.48K | $174.40K | $-10.09M | $144.98K | $130.19K | $122.33K | $222.85K | $46.56M | $10.05M |
| High Forecast | $24.67M | $21.57M | $20.12M | $16.93M | $17.53M | $18.37M | $14.66M | $7.24M | $11.50M | $12.70M | $11.54M | $6.58M | $8.44M | $223.10K | $219.68K | $5.20M | $378.92K | $341.95K | $415.70K | $22.28M | $329.95K | $262.48K | $174.40K | $-8.07M | $144.98K | $130.19K | $122.33K | $222.85K | $55.87M | $12.05M |
| Low Forecast | $22.25M | $19.46M | $18.15M | $15.27M | $16.95M | $17.66M | $14.66M | $4.82M | $11.26M | $11.45M | $10.41M | $4.39M | $5.62M | $223.10K | $219.68K | $3.47M | $378.92K | $341.95K | $415.70K | $14.86M | $329.95K | $262.48K | $174.40K | $-12.11M | $144.98K | $130.19K | $122.33K | $222.85K | $37.25M | $8.04M |
| Surprise % | - | - | - | - | - | - | - | - | -0.30% | 1.94% | 0.23% | -3.06% | -7.94% | 59.96% | 60.38% | 1.20% | 55.86% | 88.83% | 154.88% | 0.19% | -33.55% | 28.20% | 73.27% | -0.73% | -85.22% | -12.34% | -5.11% | -3569.88% | 0.89% | 1.33% |
3 analysts predict LGND's average Quarter EBITDA for Dec 23 to be $11.38M, with a high of $11.50M and a low of $11.26M. This is -51.49% lower than Ligand Pharmaceuticals's previous annual EBITDA (Sep 23) of $23.46M.
Ligand Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $18.19M | $-12.79M | $2.29M | $41.95M | $-14.53M | $404.00K | $-895.00K | $-15.38M | $-4.97M | $13.72M | $30.73M | $18.11M | $5.76M | $-6.70M | $22.09M | $-24.13M | $-7.37M | $-15.25M | $-14.42M | $666.34M | $45.28M | $5.08M |
| Avg Forecast | $33.46M | $28.55M | $26.40M | $22.90M | $21.66M | $24.81M | $19.45M | $-24.00M | $12.17M | $11.42M | $11.71M | $-21.82M | $-3.38M | $5.03M | $5.00M | $-17.25M | $15.94M | $12.30M | $16.07M | $13.62M | $12.68M | $11.42M | $8.84M | $-15.72M | $7.47M | $7.10M | $6.40M | $574.88M | $36.15M | $5.56M |
| High Forecast | $35.68M | $30.44M | $28.15M | $24.42M | $53.24M | $24.86M | $19.46M | $-19.20M | $12.98M | $12.18M | $12.49M | $-17.46M | $-2.70M | $5.03M | $5.00M | $-13.80M | $15.94M | $12.30M | $16.07M | $16.34M | $12.68M | $11.42M | $8.84M | $-12.58M | $7.47M | $7.10M | $6.40M | $689.85M | $43.38M | $6.68M |
| Low Forecast | $31.20M | $26.62M | $24.61M | $21.35M | $-38.80M | $24.77M | $19.45M | $-28.80M | $11.35M | $10.65M | $10.92M | $-26.19M | $-4.06M | $5.03M | $5.00M | $-20.70M | $15.94M | $12.30M | $16.07M | $10.90M | $12.68M | $11.42M | $8.84M | $-18.87M | $7.47M | $7.10M | $6.40M | $459.90M | $28.92M | $4.45M |
| Surprise % | - | - | - | - | - | - | - | - | 1.49% | -1.12% | 0.20% | -1.92% | 4.30% | 0.08% | -0.18% | 0.89% | -0.31% | 1.12% | 1.91% | 1.33% | 0.45% | -0.59% | 2.50% | 1.53% | -0.99% | -2.15% | -2.25% | 1.16% | 1.25% | 0.91% |
Ligand Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-24.00M, with a range of $-28.80M to $-19.20M. LGND's average Quarter net income forecast represents a -231.97% decrease compared to the company's last Quarter net income of $18.19M (Dec 23).
Ligand Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $15.99M | $14.66M | $11.29M | $10.86M | $31.13M | $17.45M | $14.59M | $18.18M | $17.74M | $12.72M | $14.71M | $12.62M | $30.08M | $15.02M | $10.07M | $9.26M | $10.28M | $9.53M | $10.99M | $11.09M | $7.64M | $7.32M |
| Avg Forecast | $17.57M | $15.36M | $14.33M | $12.05M | $12.96M | $13.48M | $10.97M | $9.27M | $8.52M | $9.04M | $8.21M | $25.79M | $12.07M | $12.73M | $12.53M | $20.38M | $21.61M | $19.50M | $23.71M | $9.49M | $18.82M | $14.97M | $9.95M | $6.04M | $8.27M | $7.43M | $6.98M | $9.57M | $6.10M | $8.02M |
| High Forecast | $18.46M | $16.14M | $15.06M | $12.67M | $13.12M | $13.75M | $10.97M | $9.27M | $8.61M | $9.50M | $8.63M | $30.94M | $14.48M | $12.73M | $12.53M | $24.46M | $21.61M | $19.50M | $23.71M | $11.39M | $18.82M | $14.97M | $9.95M | $7.24M | $8.27M | $7.43M | $6.98M | $11.48M | $7.32M | $9.62M |
| Low Forecast | $16.65M | $14.56M | $13.58M | $11.43M | $12.68M | $13.21M | $10.97M | $9.27M | $8.43M | $8.57M | $7.79M | $20.63M | $9.65M | $12.73M | $12.53M | $16.31M | $21.61M | $19.50M | $23.71M | $7.59M | $18.82M | $14.97M | $9.95M | $4.83M | $8.27M | $7.43M | $6.98M | $7.65M | $4.88M | $6.42M |
| Surprise % | - | - | - | - | - | - | - | - | 1.88% | 1.62% | 1.37% | 0.42% | 2.58% | 1.37% | 1.16% | 0.89% | 0.82% | 0.65% | 0.62% | 1.33% | 1.60% | 1.00% | 1.01% | 1.53% | 1.24% | 1.28% | 1.58% | 1.16% | 1.25% | 0.91% |
Ligand Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $9.27M, based on 1 Wall Street analysts, with a range of $9.27M to $9.27M. The forecast indicates a -42.02% fall compared to LGND last annual SG&A of $15.99M (Dec 23).
Ligand Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 14 |
| EPS | - | - | - | - | - | - | - | - | $1.03 | $-0.74 | $0.13 | $2.46 | $-0.86 | $0.02 | $-0.05 | $-0.91 | $-0.30 | $0.82 | $1.84 | $1.10 | $0.36 | $-0.42 | $1.38 | $-1.46 | $-0.43 | $-0.81 | $-0.74 | $32.59 | $2.13 | $0.24 |
| Avg Forecast | $1.82 | $1.55 | $1.43 | $1.24 | $1.18 | $1.35 | $1.06 | $0.83 | $0.66 | $0.62 | $0.64 | $0.89 | $0.77 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $1.03 | $0.69 |
| High Forecast | $1.94 | $1.65 | $1.53 | $1.33 | $2.89 | $1.35 | $1.06 | $0.89 | $0.70 | $0.66 | $0.68 | $0.95 | $0.82 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $1.24 | $0.83 |
| Low Forecast | $1.69 | $1.45 | $1.34 | $1.16 | $-2.11 | $1.34 | $1.06 | $0.78 | $0.62 | $0.58 | $0.59 | $0.83 | $0.72 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $0.82 | $0.55 |
| Surprise % | - | - | - | - | - | - | - | - | 1.56% | -1.19% | 0.20% | 2.75% | -1.11% | 0.07% | -0.19% | -2.15% | -0.34% | 1.20% | 2.06% | 1.52% | 0.51% | -0.66% | 2.81% | -3.45% | -1.04% | -2.06% | -2.09% | 1.69% | 2.07% | 0.35% |
According to 1 Wall Street analysts, Ligand Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.83, with a low estimate of $0.78 and a high estimate of $0.89. This represents a -19.03% decrease compared to LGND previous annual EPS of $1.03 (Dec 23).
Ligand Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| ANNX | Annexon | $4.88 | $14.00 | 186.89% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.25 | $20.00 | 142.42% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| ETNB | 89bio | $7.98 | $12.00 | 50.38% | Buy |
| BGNE | BeiGene | $179.06 | $267.33 | 49.30% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| LGND | Ligand Pharmaceuticals | $120.43 | $140.50 | 16.67% | Buy |
| VRDN | Viridian Therapeutics | $20.82 | $22.75 | 9.27% | Buy |